Fate Therapeutics Inc.

32.84-1.30-3.81%Vol 1.51M1Y Perf -64.34%
Aug 9th, 2022 16:00 DELAYED
BID30.00 ASK32.80
Open32.95 Previous Close34.14
Pre-Market- After-Market32.73
 - -  -0.11 -0.33%
Target Price
75.73 
Analyst Rating
Strong Buy 1.47
Potential %
130.60 
Finscreener Ranking
★★★★+     55.56
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     52.18
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     61.36
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
19.59 
Earnings Rating
Sell
Market Cap3.19B 
Earnings Date
3rd Aug 2022
Alpha0.04 Standard Deviation0.19
Beta1.58 

Today's Price Range

31.3733.52

52W Range

17.1097.43

5 Year PE Ratio Range

-21.00-6.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
11.46%
1 Month
13.76%
3 Months
52.75%
6 Months
-16.63%
1 Year
-64.34%
3 Years
82.47%
5 Years
1 026.73%
10 Years
-

TickerPriceChg.Chg.%
FATE32.84-1.3000-3.81
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
-
-380.90
-368.80
-864.70
-
RevenueValueIndustryS&P 500US Markets
49.71M
0.51
101.21
78.28
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.86-0.798.14
Q01 2022-0.78-0.6812.82
Q04 2021-0.68-0.72-5.88
Q03 2021-0.58-0.571.72
Q02 2021-0.52-0.58-11.54
Q01 2021-0.42-0.48-14.29
Q04 2020-0.38-0.380.00
Q03 2020-0.29-0.36-24.14
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.86-6.17Negative
9/2022 QR-0.86-3.61Negative
12/2022 FY-3.37-1.81Negative
12/2023 FY-3.94-4.79Negative
Next Report Date-
Estimated EPS Next Report-0.86
Estimates Count12
EPS Growth Next 5 Years %-
Volume Overview
Volume1.51M
Shares Outstanding97.00K
Shares Float72.14M
Trades Count21.58K
Dollar Volume49.73M
Avg. Volume1.46M
Avg. Weekly Volume1.57M
Avg. Monthly Volume1.20M
Avg. Quarterly Volume1.61M

Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 34.14 per share at the end of the most recent trading day (a 2.15% change compared to the prior day closing price) with a volume of 2.01M shares and market capitalization of 3.19B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.

The one-year performance of Fate Therapeutics Inc. stock is -64.34%, while year-to-date (YTD) performance is -41.65%. FATE stock has a five-year performance of 1026.73%. Its 52-week range is between 17.1 and 97.43, which gives FATE stock a 52-week price range ratio of 19.59%

Fate Therapeutics Inc. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 4.84, a price-to-sale (PS) ratio of 59.64, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.22%, a ROC of -28.41% and a ROE of -33.75%. The company’s profit margin is -%, its EBITDA margin is -368.80%, and its revenue ttm is $49.71 Million , which makes it $0.51 revenue per share.

Of the last four earnings reports from Fate Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Strong Buy (1.47), with a target price of $75.73, which is +130.60% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fate Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.16, ATR14 : 2.87, CCI20 : 211.88, Chaikin Money Flow : 0.06, MACD : 1.47, Money Flow Index : 41.79, ROC : 2.40, RSI : 43.33, STOCH (14,3) : 60.76, STOCH RSI : 1.00, UO : 47.16, Williams %R : -39.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $712 349), Bahram Valamehr (Sold 288 340 shares of value $13 310 127 ), Cindy Tahl (Option Excercise at a value of $1 637 500), Cindy Tahl (Sold 276 314 shares of value $14 209 201 ), Edward J. Dulac (Option Excercise at a value of $615 384), Edward J. Dulac (Sold 24 704 shares of value $1 609 193 ), J. Scott Wolchko (Option Excercise at a value of $639 035), J. Scott Wolchko (Sold 264 968 shares of value $12 897 133 ), John D. Mendlein (Option Excercise at a value of $51 446), John D. Mendlein (Sold 32 926 shares of value $1 136 286 ), Karin Jooss (Sold 1 483 shares of value $33 842 ), Mark Plavsic (Sold 3 719 shares of value $91 525 ), Robert M. Hershberg (Sold 672 shares of value $15 288 ), Shefali Agarwal (Sold 1 648 shares of value $36 809 ), Timothy P. Coughlin (Sold 1 439 shares of value $32 824 ), Yu-Waye Chu (Option Excercise at a value of $367 200), Yu-Waye Chu (Sold 46 581 shares of value $2 165 884 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
13 (76.47 %)
12 (75.00 %)
12 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (23.53 %)
4 (25.00 %)
3 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.47
Strong Buy
1.50
Strong Buy
1.40

Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

CEO: J. Scott Wolchko

Telephone: +1 858 875-1800

Address: 3535 General Atomics Court, San Diego 92121, CA, US

Number of employees: 279

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

70%30%

Bearish Bullish

58%42%

TipRanks News for FATE

Tue, 09 Aug 2022 02:21 GMT Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Arcus Biosciences (RCUS) and Arvinas Holding Company (ARVN)

- TipRanks. All rights reserved.

Fri, 05 Aug 2022 03:37 GMT Fate Therapeutics (FATE) Receives a Hold from Robert W. Baird

- TipRanks. All rights reserved.

Thu, 04 Aug 2022 02:26 GMT Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

Thu, 28 Jul 2022 09:25 GMT Fate Therapeutics (FATE) Initiated with a Hold at Needham

- TipRanks. All rights reserved.

Tue, 28 Jun 2022 12:26 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Fate Therapeutics (FATE) and Kezar Life Sciences (KZR)

- TipRanks. All rights reserved.

Thu, 19 May 2022 12:39 GMT Fate Therapeutics (FATE) Gets a Buy Rating from SVB Securities

- TipRanks. All rights reserved.

Mon, 16 May 2022 10:25 GMT Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Virios Therapeutics (VIRI) and Ocuphire Pharma (OCUP)

- TipRanks. All rights reserved.

Sun, 08 May 2022 15:10 GMT Fate Therapeutics (FATE) Has a New Rating from SVB Securities

- TipRanks. All rights reserved.

Tue, 01 Mar 2022 13:50 GMT Fate Therapeutics (FATE) Receives a Hold from BMO Capital

- TipRanks. All rights reserved.

News

Stocktwits